伊芙美尔医疗 ICCC 深 沪
等待开盘 09-11 09:30:00 美东时间
6.16
0.000
0.00%
华盛通- 最 高6.3479
- 今 开6.13
- 成交量 4833股
- 最 低 6.13
- 昨 收 6.16
- 总市值 5567.04万
- 52周最高 7.60
- 市盈率 静 --
- 换手率 0.05%
- 52周最低 3.38
- 委 比 -63.93%
- 总股本 903.74万
- 历史最高 13.20
- 量 比 1.51
- 振 幅 3.54%
- 历史最低 3.19
- 每 手 1
- 风险率 1.06%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多【爱建电子】电子行业周报：Amazfit产业链迎来业绩拐点
（来源：爱建证券研究所） Amazfit产业链迎来业绩拐点 -爱建电子行业周报- 本报告发布于2025年08月20日 投资要点： 被动元件...
08-20 17:58
电话会总结 ｜ ImmuCell(ICCC)2025财年Q2业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• **财务业绩**： - 2025年第二季度产品销售额同比增长18%，增加了97.2万美元；2025年上半年产品销售额同比增长14%，增加了180万美元；截至2025年6月30日的过去12个月产品销售额同比增长22%，增加了510万美元。 - 2025年第二季度调整后EBITDA为143万美元，而2024年同期为-11.9万美元；2025年上半年调整后EBITDA为370万美元，而2024年同期为-16.1万美元；截至2025年6月30日的过去12个月调整后EBITDA为530万美元，而2024年同期为-37万美元。 -
08-16 12:05
ImmuCell Reports Strong Sales Growth and Profitability
Immucell ( ($ICCC) ) has released its Q2 earnings. Here is a breakdown of the i...
08-16 11:55
ImmuCell outlines cautious H2 outlook as capacity expansion supports First Defense suite
Earnings Call Insights: ImmuCell Corporation (ICCC) Q2 2025 Management View Michael F. Brigham, President and CEO, stated that ImmuCell is “in the midst of a very positive transition,” having complete...
08-15 23:04
Earnings Scheduled For August 14, 2025
Companies Reporting Before The Bell • Sunlands Technology (NYSE:STG) is likely ...
08-14 16:32
ImmuCell Announces Bank Debt Refinancing
ImmuCell Corporation refinanced a portion of its bank debt, replacing loans with higher interest rates (7% and 8%) from Maine Community Bank (MCB) and Finance Authority of Maine (FAME) with a new $2.3 million loan at 6.5% from MCB, extending repayment terms to 2030. CEO Michael Brigham expressed gratitude for ongoing partnerships with MCB and FAME, noting the new loan allows FAME funds to support others in Maine. The company plans a conference ca...
08-12 20:05
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2025
ImmuCell Corporation (NASDAQ: ICCC) has scheduled a conference call for Friday, August 15, 2025, at 9:00 AM ET, to discuss Q2 2025 unaudited financial results, which will be released after markets close on August 14, 2025. The call will be accessible via (844) 855-9502 (toll-free) or (412) 317-5499 (international). A replay will be available until August 22, 2025. The company anticipates no change to the preliminary Q2 2025 sales results disclose...
08-07 12:00
ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 of 2025
ImmuCell Corporation reported preliminary, unaudited sales results for the second quarter of 2025, showing a 18% increase compared to the same period in 2024. Product sales for the three-month, six-month, nine-month, and twelve-month periods ended June 30, 2025, rose by 18%, 14%, 25%, and 22% respectively. The company has reduced its order backlog to under $100,000, reflecting improved production output and inventory replenishment. ImmuCell is ev...
07-09 12:00
ImmuCell initiates CEO succession search ahead of planned 2026 retirement
ImmuCell (NASDAQ:ICCC) begins search for a new president and chief executive officer. Current CEO Michael F. Brigham plans to retire from full-time work by early 2026. Brigham's financial officer duti...
06-25 20:53
ImmuCell Embarks on CEO Succession Planning Process
ImmuCell Corporation announced it is seeking a new CEO as current President and CEO Michael F. Brigham, who joined in 1989, plans to retire by early 2026. Brigham will continue to assist with the leadership transition and intends to remain on the Board of Directors through his elected term ending in June 2026. The Board aims to identify a top candidate by year-end 2025.
06-25 12:00
